Market Access What rare disease commercialisation in Europe teaches us - a... Rare disease launches are the ultimate stress test for European commercialisation.
Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.
Market Access Unlocking oncology access: What the OECD findings mean for m... New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
